RBC Capital raises price targets on Bausch Health and Chemed
RBC Capital kept Sector Perform ratings on Bausch Health and Chemed and lifted both price targets, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RBC Capital kept its Sector Perform rating on Bausch Health Companies and raised its price target from $9 to $10, an increase of 11.1%. According to TradingView, the new target implies upside of 3.4% from the October 28 close of $9.67.
RBC Capital also kept its Sector Perform rating on Chemed and raised its price target from $548 to $585, a rise of 6.8%. Measured from the October 28 close of $533.36, the implied upside is 9.7%. TradingView attributes the reference data to Benzinga.
why it matters
Price target revisions are routine for analysts, and on their own they rarely move a stock much. The notable point here is that the ratings did not change: RBC adjusted its price targets but kept its recommendations. For investors, this is just one of many views on these companies, not a signal to act.
tags
instruments
sources
- RBC Capital maintains Bausch Health Companies at Sector Perform, raises price target to $10 from $9 — TradingView, 29 October 2026 at 19:17 UTC
- RBC Capital maintains Chemed at Sector Perform, raises price target to $585 from $548 — TradingView, 29 October 2026 at 19:23 UTC
- RBC Capital maintains Fortive at Sector Perform, raises price target to $68 from $59 — TradingView, 29 October 2026 at 19:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗